[卫生技术评估：一种基于价值的医疗技术评估工具。细胞培养衍生四价流感疫苗Flucelvax Tetra 2.0的重新评估] - Suppr

[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].

作者信息

Calabrò Giovanna Elisa, Boccalini Sara, Bechini Angela, Panatto Donatella, Domnich Alexander, Lai Piero Luigi, Amicizia Daniela, Rizzo Caterina, Pugliese Andrea, DI Pietro Maria Luisa, Zanella Beatrice, Parente Flavio, Trombetta Carlo Simone, Saraceno Giovanni, Sottile Sara, Abreha Fasika Molla, Giacchetta Irene, Properzi Sara, Santolini Giulia, D'Ambrosio Floriana, Maida Ada, Scardigno Anna, LA Gatta Emanuele, Petrella Luigi, Bonanni Paolo, DE Waure Chiara

机构信息

Sezione di Igiene, Dipartimento Universitario di Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Roma, Italia.

VIHTALI (Value In Health Technology and Academy for Leadership & Innovation), Spin-off dell'Università Cattolica del Sacro Cuore, Roma, Italia.

出版信息

J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec.

DOI:10.15167/2421-4248/jpmh2022.63.4s1

PMID:37034835

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10079375/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0940/10079375/d3587299f48c/jpmh-2022-04-S1-g006.jpg

相似文献

[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].[卫生技术评估：一种基于价值的医疗技术评估工具。细胞培养衍生四价流感疫苗Flucelvax Tetra 2.0的重新评估]

J Prev Med Hyg. 2023 Mar 2;63(4 Suppl 1):E1-E140. doi: 10.15167/2421-4248/jpmh2022.63.4s1. eCollection 2022 Dec.

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax Tetra/Flucelvax Quadrivalent): A Review in the Prevention of Influenza.细胞四价流感病毒灭活疫苗（Flucelvax Tetra/Flucelvax Quadrivalent）：预防流感的综述。

Drugs. 2019 Aug;79(12):1337-1348. doi: 10.1007/s40265-019-01176-z.

Intradermal delivery of a quadrivalent cell-based seasonal influenza vaccine using an adjuvanted skin patch vaccination platform.使用佐剂皮肤贴片疫苗接种平台进行四价细胞季节性流感疫苗的皮内接种。

Vaccine. 2023 Jan 9;41(2):304-314. doi: 10.1016/j.vaccine.2022.10.006. Epub 2022 Dec 13.

Effect of Repeat Vaccination on Immunogenicity of Quadrivalent Cell-Culture and Recombinant Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized, Open-Label Trial.18-64 岁医护人员重复接种四价细胞培养和重组流感疫苗对免疫原性的影响：一项随机、开放标签试验。

Clin Infect Dis. 2023 Feb 8;76(3):e1168-e1176. doi: 10.1093/cid/ciac683.

Flucelvax (Optaflu) for seasonal influenza.用于季节性流感的Flucelvax（Optaflu）。

Expert Rev Vaccines. 2015 Jun;14(6):789-804. doi: 10.1586/14760584.2015.1039520.

Comparison of the Immunogenicity of Cell Culture-Based and Recombinant Quadrivalent Influenza Vaccines to Conventional Egg-Based Quadrivalent Influenza Vaccines Among Healthcare Personnel Aged 18-64 Years: A Randomized Open-Label Trial.18-64 岁医护人员细胞培养型和重组型四价流感疫苗与传统鸡胚型四价流感疫苗免疫原性比较：一项随机、开放标签试验。

Clin Infect Dis. 2021 Dec 6;73(11):1973-1981. doi: 10.1093/cid/ciab566.

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.疫苗预防和控制季节性流感：免疫实践咨询委员会的建议-美国，2022-23 流感季节。

MMWR Recomm Rep. 2022 Aug 26;71(1):1-28. doi: 10.15585/mmwr.rr7101a1.

A randomized controlled trial of antibody response to 2018-19 cell-based vs. egg-based quadrivalent inactivated influenza vaccine in children.一项评估儿童对 2018-19 年细胞基质与鸡胚基质四价流感灭活疫苗抗体反应的随机对照试验。

Vaccine. 2020 Jul 14;38(33):5171-5177. doi: 10.1016/j.vaccine.2020.06.023. Epub 2020 Jun 21.

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil.南半球四价流感病毒裂解疫苗的免疫原性和安全性：一项在巴西开展的针对成年人的III期开放标签研究。

Braz J Infect Dis. 2017 Jan-Feb;21(1):63-70. doi: 10.1016/j.bjid.2016.10.003. Epub 2016 Nov 29.

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax Tetra/Flucelvax Quadrivalent): A Review in the Prevention of Influenza.对《基于细胞的四价流感病毒灭活疫苗（Flucelvax Tetra/Flucelvax四价）：预防流感的综述》的更正

Drugs. 2019 Dec;79(18):2009. doi: 10.1007/s40265-019-01237-3.

引用本文的文献

[Not Available].[无可用内容]。

J Prev Med Hyg. 2025 Apr 15;66(1 Suppl 2):E1-E56. doi: 10.15167/2421-4248/jpmh2025.66.1s2. eCollection 2025 Apr.

The Evolution of Annual Immunization Recommendations Against Influenza in Italy: The Path to Precision Vaccination.意大利年度流感免疫接种建议的演变：精准接种之路。

Vaccines (Basel). 2025 Mar 27;13(4):356. doi: 10.3390/vaccines13040356.

Health Technology Assessment of Vaccines in Italy: History and Review of Applications.意大利疫苗的卫生技术评估：历史与应用综述

Vaccines (Basel). 2024 Sep 24;12(10):1090. doi: 10.3390/vaccines12101090.

The economic and fiscal impact of incremental use of cell-based quadrivalent influenza vaccine for the prevention of seasonal influenza among healthcare workers in Italy.细胞基四价流感疫苗在意大利用于预防季节性流感的医护人员中的增量使用的经济和财政影响。

Health Res Policy Syst. 2024 Mar 22;22(1):36. doi: 10.1186/s12961-024-01122-w.

Three seasons of enhanced safety surveillance of a cell culture-based quadrivalent influenza vaccine.三季细胞培养型四价流感疫苗强化安全性监测。

Hum Vaccin Immunother. 2023 Aug;19(2):2261689. doi: 10.1080/21645515.2023.2261689. Epub 2023 Oct 3.

本文引用的文献

Importance and value of adjuvanted influenza vaccine in the care of older adults from a European perspective - A systematic review of recently published literature on real-world data.从欧洲角度看，佐剂流感疫苗在老年人护理中的重要性和价值 - 对近期真实世界数据文献的系统评价。

Vaccine. 2022 May 11;40(22):2999-3008. doi: 10.1016/j.vaccine.2022.04.019. Epub 2022 Apr 19.

Seasonal influenza in children: Costs for the health system and society in Europe.儿童季节性流感：欧洲卫生系统和社会的成本。

Influenza Other Respir Viruses. 2022 Sep;16(5):820-831. doi: 10.1111/irv.12991. Epub 2022 Apr 15.

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment.《意大利老年人用新型四价佐剂流感疫苗：卫生技术评估》。

Int J Environ Res Public Health. 2022 Mar 31;19(7):4166. doi: 10.3390/ijerph19074166.

Efficacy, immunogenicity, and safety of available vaccines in children on biologics: A systematic review and meta-analysis.生物制剂治疗儿童的现有疫苗的疗效、免疫原性和安全性：系统评价和荟萃分析。

Vaccine. 2022 Apr 26;40(19):2679-2695. doi: 10.1016/j.vaccine.2022.03.041. Epub 2022 Mar 31.

Comparative efficacy and safety of vaccines to prevent seasonal influenza: A systematic review and network meta-analysis.预防季节性流感疫苗的比较疗效与安全性：一项系统评价和网状Meta分析

EClinicalMedicine. 2022 Mar 25;46:101331. doi: 10.1016/j.eclinm.2022.101331. eCollection 2022 Apr.

The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.疫苗接种的价值：依据基于价值的医疗保健方法构建科学证据。

Front Public Health. 2022 Mar 9;10:786662. doi: 10.3389/fpubh.2022.786662. eCollection 2022.

Acceptance of COVID-19 and Influenza Vaccine Co-Administration: Insights from a Representative Italian Survey.接受新冠病毒肺炎和流感疫苗联合接种：来自一项具有代表性的意大利调查的见解。

J Pers Med. 2022 Jan 20;12(2):139. doi: 10.3390/jpm12020139.

Systematic review of the efficacy, effectiveness and safety of MF59 adjuvanted seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.MF59 佐剂季节性流感疫苗预防 18 岁及以上个体实验室确诊流感的疗效、效果和安全性的系统评价。

Rev Med Virol. 2023 May;33(3):e2329. doi: 10.1002/rmv.2329. Epub 2022 Feb 10.

Systematic review of the efficacy, effectiveness and safety of high-dose seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.系统评价高剂量季节性流感疫苗预防 18 岁及以上个体实验室确诊流感的疗效、效果和安全性。

Rev Med Virol. 2023 May;33(3):e2330. doi: 10.1002/rmv.2330. Epub 2022 Feb 4.

Systematic review of the efficacy, effectiveness and safety of recombinant haemagglutinin seasonal influenza vaccines for the prevention of laboratory-confirmed influenza in individuals ≥18 years of age.对 18 岁及以上个体中预防实验室确诊流感的重组血凝素季节性流感疫苗的疗效、效果和安全性的系统评价。

Rev Med Virol. 2023 May;33(3):e2331. doi: 10.1002/rmv.2331. Epub 2022 Feb 2.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Health Technology Assessment: a value-based tool for the evaluation of healthcare technologies. Reassessment of the cell-culture-derived quadrivalent influenza vaccine: Flucelvax Tetra 2.0].

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献